
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics rose 41.5% from $0.62 to $0.88, ahead of the S&P 500's +11.0%. Its worst day was Sep 3 (−14.4%), and its low came Feb 17 at $0.48.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics closed at its lowest level of the year, 23.7% below where the year started.
−11.0% · S&P 500 +0.2%
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics shares rose 20.0%, while the S&P 500 rose 1.0%.
Story events cover the past 12 months · Times ET
+20.0% · S&P 500 +1.0%
EPS of $-0.20 beat the $-0.39 estimate on $0.00 revenue.
+9.2% · S&P 500 +2.9%
EPS of $-0.19 was reported on $0.00 revenue.
0.0% · S&P 500 −0.1%
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics closed at its highest level of the year, 131.3% above where the year started.
+11.6% · S&P 500 −0.1%
EPS of $-0.35 was reported on $0.00 revenue.
+9.6% · S&P 500 −0.5%
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics shares rose 20.0%, while the S&P 500 rose 0.0%.
+20.0% · S&P 500 0.0%
EPS of $-0.14 was reported on $0.00 revenue.
−7.3% · S&P 500 −1.0%
Where it ended: a close of $0.88 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 15, 2027.
Nothing in the past 12 months.
All BCLI analyst actionsNothing in the past 12 months.
All BCLI dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCLI and SPY from Benzinga historical bars. Not investment advice.